AR083591A1 - Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona - Google Patents

Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona

Info

Publication number
AR083591A1
AR083591A1 ARP110103993A ARP110103993A AR083591A1 AR 083591 A1 AR083591 A1 AR 083591A1 AR P110103993 A ARP110103993 A AR P110103993A AR P110103993 A ARP110103993 A AR P110103993A AR 083591 A1 AR083591 A1 AR 083591A1
Authority
AR
Argentina
Prior art keywords
pyrimidin
bis
amino
oxobutil
hydropired
Prior art date
Application number
ARP110103993A
Other languages
English (en)
Inventor
Ki Sook Park
Jung Min Yun
Bong Chan Kim
Kyu Young Kim
Ji Hye Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR083591A1 publication Critical patent/AR083591A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere al 1,5 hidrato de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, un proceso para prepararlo, y una composición farmacéutica para inhibir la DPP-IV, que comprende dicho compuesto como componente activo.Reivindicación 1: 1,5 hidrato de sal de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidro-pirido [3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, caracterizado porque tiene un contenido de agua en el rango que oscila entre 3,5 y 5,5 %.
ARP110103993A 2010-11-01 2011-10-28 Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona AR083591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01

Publications (1)

Publication Number Publication Date
AR083591A1 true AR083591A1 (es) 2013-03-06

Family

ID=45995015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103993A AR083591A1 (es) 2010-11-01 2011-10-28 Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona

Country Status (28)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20180464A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TWI617554B (zh) 2013-03-06 2018-03-11 健生藥品公司 組織胺ｈ受體之苯并咪唑－２－基嘧啶調控劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208498B2 (en) * 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2004210149A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
CA2814357A1 (en) 2012-05-10
DOP2013000090A (es) 2018-06-30
NZ609644A (en) 2016-02-26
US8859567B2 (en) 2014-10-14
PE20180464A1 (es) 2018-03-06
BR112013010586A2 (pt) 2016-08-09
PE20140392A1 (es) 2014-03-22
CL2013001137A1 (es) 2013-09-06
UA106445C2 (ru) 2014-08-26
AP3287A (en) 2015-05-31
EP2635580A4 (en) 2014-04-02
TWI519533B (zh) 2016-02-01
CO6710945A2 (es) 2013-07-15
US20130203787A1 (en) 2013-08-08
EP2635580B1 (en) 2015-08-12
EA201390644A1 (ru) 2014-11-28
IL225808A0 (en) 2013-06-27
TW201245189A (en) 2012-11-16
MX2013004776A (es) 2013-11-04
AU2011324253A1 (en) 2013-05-02
PE20240220A1 (es) 2024-02-16
KR101446789B1 (ko) 2014-10-01
WO2012060590A3 (en) 2012-06-28
MY156428A (en) 2016-02-26
MA34625B1 (fr) 2013-10-02
WO2012060590A2 (en) 2012-05-10
MX341584B (es) 2016-08-25
JP6193762B2 (ja) 2017-09-06
IL225808A (en) 2016-08-31
AU2011324253B2 (en) 2015-10-29
UY33696A (es) 2012-04-30
CN103189375A (zh) 2013-07-03
ECSP13012599A (es) 2013-07-31
JP2013540810A (ja) 2013-11-07
ZA201302646B (en) 2014-01-29
EA024679B1 (ru) 2016-10-31
CN103189375B (zh) 2016-08-10
CA2814357C (en) 2015-07-07
SG189931A1 (en) 2013-06-28
GEP20156218B (en) 2015-01-12
AP2013006866A0 (en) 2013-05-31
EP2635580A2 (en) 2013-09-11
KR20120046069A (ko) 2012-05-09

Similar Documents

Publication Publication Date Title
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR084551A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DUAL DE mTOR/CINASA PI3
CL2014000343A1 (es) Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
CL2013002688A1 (es) Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer.
UY34870A (es) Cristales de sal
BRPI1006869A2 (pt) estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil
CL2013002166A1 (es) Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia.
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
CL2010001488A1 (es) Proceso para preparar 2,4-dioxo-1,2,4-tetrahidropirido[2,3-d]pirimidin-7-il-fenil sustituido y 2,4-bis[3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il-fenil-sustituido; sal fumarato de {5-[2,4-bis[(3s)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il]-2-metoxifenil}metanol; composicon farmaceutica; y uso para tratar el cancer.
MY159492A (en) Solid pharmaceutical formulation with delayed release
AR083591A1 (es) Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona
PE20142358A1 (es) Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
BR112016008994A2 (pt) Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
BR112012024239A2 (pt) composição para tratamento de trombocitemia essencial
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
BR112015004127A2 (pt) sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor
UY31601A1 (es) Nueva sal derivada de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]-quinolin-3-carboxamida.
CU20150047A7 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.
AR052589A1 (es) Tetrahidrato acido de la sal de arginina de benzoquinolizina -2-carboxilico

Legal Events

Date Code Title Description
FB Suspension of granting procedure